L-dopa modulates motor cortex excitability in Alzheimer's disease patients

J Neural Transm (Vienna). 2008 Sep;115(9):1313-9. doi: 10.1007/s00702-008-0082-z. Epub 2008 Jul 2.

Abstract

In Alzheimer's disease (AD), transcranial magnetic stimulation (TMS) studies have shown abnormalities of motor cortical excitability, such as a decreased intra-cortical inhibition (ICI) and changes in resting motor threshold (rMT). We studied the effects of L-dopa on rMT and ICI in a cohort of moderate AD patients after paired-pulse TMS. Results were compared with a control group of healthy subjects. As expected, AD patients showed a significant reduction in ICI and a lower rMT. L-dopa administration (soluble form, melevodopa 200 mg) promptly reversed the ICI impairment up to normalization. This effect was specific, since it was not mimicked in control subjects. These results indicate a possible role of dopamine in modulating AD cortical excitability, thus suggesting an interaction between dopaminergic ascending pathways and endogenous intracortical transmitters. In addition, considering that L-dopa showed a pharmacological profile similar to the one of cholinomimetics, L-dopa might represent a reliable tool to study new therapeutic perspective and strategies for AD.

MeSH terms

  • Acetylcholine / metabolism
  • Afferent Pathways / drug effects
  • Afferent Pathways / metabolism
  • Afferent Pathways / physiopathology
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / physiopathology
  • Cholinergic Agents / pharmacology
  • Cholinergic Agents / therapeutic use
  • Dopamine / metabolism*
  • Dopamine Agents / pharmacology
  • Evoked Potentials, Motor / drug effects
  • Evoked Potentials, Motor / physiology
  • Female
  • Humans
  • Levodopa / analogs & derivatives
  • Levodopa / pharmacology*
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Motor Cortex / drug effects*
  • Motor Cortex / metabolism*
  • Motor Cortex / physiopathology
  • Neural Inhibition / drug effects
  • Neural Inhibition / physiology
  • Neural Pathways / drug effects
  • Neural Pathways / metabolism
  • Neural Pathways / physiopathology
  • Nootropic Agents / pharmacology
  • Reaction Time / drug effects
  • Reaction Time / physiology
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Time Factors
  • Transcranial Magnetic Stimulation

Substances

  • Cholinergic Agents
  • Dopamine Agents
  • Nootropic Agents
  • Levodopa
  • levodopa methyl ester
  • Acetylcholine
  • Dopamine